Save

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

EARLY_PHASE1RECRUITING

This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.

Simpliy with AI

Study details:

APG-2575 will be administered orally, once daily for consecutive 4 weeks as one cycles. Initially, the start dose is 20mg. Single patient cohorts will be evaluated, the dose of APG-2575 will be increased in subsequent cohorts, to 50 mg, 100 mg, 200 mg, 400 mg, 600mg and 800mg accordingly.

If there is any one of the following event is observed, a DLT, two drug related Grade 2 toxicities or one drug related ≥ Grade 3 toxicity, or laboratory or clinical TLS, or suspected hypersensitivity reaction occur in Cycle 1, or dose level of 400 mg is reached, the dose escalation will convert to the standard 3+3 design, If ≥ 2/6 patients develop DLT at any dose level dose escalation will cease and the dose level immediately below will be expanded to 6 patients. If ≤ 1/6 patients develop a DLT at the highest dose reached this will be declared the MTD. After the MTD is defined, a maximum of 20 patients will be treated at that dose level.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Age ≥18 years old.

Histologically confirmed diagnosis of either one of the B-cell hematologic malignancies including multiple myeloma, chronic lymphocytic leukemia, lymphoplasmacytic lymphoma, and non-Hodgkin's lymphoma such as mantle cell lymphoma, diffuse large B cell lymphoma, Waldenstrom macroglobulinemia (WM) and acute myeloid leukemia

Patient must have relapsed or refractory to, intolerant to, or are considered ineligible for therapies known to provide clinical benefit. In addition, AML Patients will be eligible if they have failed standard induction regimen, are not considered candidate for further chemotherapy or stem cell transplantation or have primary refractory AML.

Life expectancy ≥ 3 months.

Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -1 in dose escalation ; 0-2 in dose expansion.

QTc interval ≤450ms in males, and ≤470ms in females.

Adequate bone marrow function independent of growth factor:

Absolute neutrophil count (ANC) ≥1.0 X 109/L.

Hemoglobin ≥ 8.0 g/dL.

Platelets count ≥ 30 X 109/L (entry platelet count must be independent of transfusion within 7 days of first dose).

Adequate renal and liver function as indicated by:

Exclusion criteria

Prior history of allogeneic cell transplant.

Subjects have been diagnosed with Burkitt's lymphoma, Burkitt-like lymphoma, or lymphoblastic lymphoma/leukemia.

Received chemotherapy within 14 days (42 days for nitrosoureas or mitomycin C) prior to entering the study.

Received biologic (< 28 days), small molecule targeted therapies (< 5 half-life) or other anti-cancer therapy within 21 days of study entry.

Radiation within 14 days of study entry, thoracic radiation within 28 days of study entry.

Has gastrointestinal conditions that could affect the absorption of APG-2575 in the opinion of the Investigator.

Has known active central nervous system (CNS) involvement.

Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not recover to ≤ Grade 1 except alopecia or neuropathy.

Concurrent treatment with an investigational agent, 14 days for small molecular agents and/or 28 days for biologics treatment prior to the first dose of therapy.

Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients with active wound healing, patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry.

Unstable angina, myocardial infarction, or a coronary revascularization procedure within 180 days of study entry.

Active rheumatoid arthritis (RA), active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation.

Active infection requiring systemic antibiotic/ antifungal medication, known clinically active hepatitis B or C infection, or on antiretroviral therapy for HIV disease.

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2018-08-07

Primary completion: 2024-09-15

Study completion finish: 2025-02-15

Study type

TREATMENT

Phase

EARLY_PHASE1

Trial ID

NCT03537482

Intervention or treatment

DRUG: APG-2575

Conditions

• Hematologic Malignancies

Image related to Hematologic Malignancies

Condition: Hematologic Malignancies
DRUG: APG-2575
Fitzroy, Victoria, Australia and more
Sponsor: Ascentage Pharma Group Inc.

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

St. Vincent Hospital

Research sites nearby

Select from list below to view details:

St. Vincent Hospital
Fitzroy, Victoria, Australia
Epworth Healthcare
Richmond, Victoria, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: single-agent, open-label, Phase I study of APG-2575 The study consists of the dose escalation stage and the dose expansion stage	DRUG: APG-2575 APG-2575 will be administered as an oral tablet

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Maximum Tolerated Dose (MTD)	Patients with APG-2575 treatment related adverse events (AE), serious adverse events (SAE) will be assessed according NCI CTCAE Version 4.0	28 days

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Maximum plasma concentration (Cmax)	Maximum plasma concentration (Cmax) will be assessed in the patients treated with APG-2575	28 days
Area under the plasma concentration versus time curve (AUC)	Area under the plasma concentration versus time curve (AUC) of APG-2575 will be assessed in the patients treated with APG-2575	28 days
Anti-tumor effects of APG-2575	Response will be evaluated every 2 cycles (8 weeks), by the investigator based on disease specific criteria.	up to 2 years

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies